Whole-genome analyses of patient samples have revealed that the number of FGFR mutations and amplifications are generally very low in GBM (FGFR1: 51/3068 samples, FGFR2: 12/2662; FGFR3: 16/2887; FGFR4: 9/2456; cancer.sanger.ac.uk; [17]). Here, FGFR2 is linked to glioblastoma.